MAFLD stands for metabolic dysfunction-associated fatty liver disease, a term proposed in 2020 to replace the older label NAFLD (nonalcoholic fatty liver disease). The change was not just cosmetic. MAFLD reframes fatty liver as a condition rooted in metabolic problems like obesity, type 2 diabetes, and insulin resistance, rather than defining it by what it is not (i.e., “nonalcoholic”). That shift in framing has practical consequences for who gets diagnosed, how quickly, and what other health risks doctors look for alongside the liver itself.
Why the Name Changed
For decades, NAFLD was the go-to abbreviation. But the name carried baggage. “Nonalcoholic” required doctors to first rule out significant alcohol use, plus a laundry list of other liver diseases, before arriving at a diagnosis. That exclusion-based approach slowed things down and left many patients in diagnostic limbo. It also carried stigma: some patients felt the term implied a drinking problem they did not have, and “fatty” was considered pejorative by others.
The MAFLD label flips the diagnostic logic. Instead of excluding causes, it asks whether someone has fat in the liver alongside at least one metabolic condition. Several leading hepatology and gastroenterology societies have adopted it because it offers a simpler bedside diagnosis, removes the requirement to exclude other coexisting liver diseases, and reduces the stigma tied to the old terminology.1PubMed Central. MAFLD: How is it different from NAFLD? It is worth noting that a separate renaming effort led by a large international consortium settled on “MASLD” (metabolic dysfunction-associated steatotic liver disease) as yet another label. The coexistence of MAFLD, NAFLD, and MASLD in the medical literature can be confusing, but all three describe overlapping patient populations with fat-related liver disease driven by metabolic dysfunction.2PubMed Central. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
A meta-analysis comparing the two older frameworks found substantial overlap between people who qualify under MAFLD criteria and those who qualify under NAFLD criteria, but MAFLD consistently identified more individuals with actual liver damage than NAFLD did. In other words, the newer definition catches people the old one missed, making it a better population-level tool.3PubMed. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups
How MAFLD Is Diagnosed
A MAFLD diagnosis requires two things: evidence of fat in the liver (usually spotted on ultrasound, though other imaging works too) and at least one of three metabolic conditions. You need the fat plus any one of the following:
- Overweight or obesity: a body mass index above a certain threshold (generally above 25 kg/m², or above 23 kg/m² in Asian populations).
- Type 2 diabetes: either already diagnosed or meeting standard diagnostic criteria.
- Metabolic dysregulation in a lean person: at least two metabolic risk factors such as elevated blood pressure, abnormal blood lipids, high waist circumference, or insulin resistance, even if body weight is normal.
That third pathway is what makes the MAFLD framework more inclusive than older definitions. A lean person with fatty liver and a couple of metabolic red flags qualifies, whereas under NAFLD criteria they might have been overlooked or told they were fine because they were not overweight.4PubMed Central. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease A cross-sectional study in China used very similar criteria, adjusting the BMI threshold to greater than 23 kg/m² for that population, and found the approach practical for routine screening.5PubMed Central. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
How Common It Is
MAFLD is not a niche condition. A 2025 systematic analysis of the Global Burden of Disease data estimated that the worldwide crude prevalence rose from about 11% in 1990 to roughly 16% in 2021, affecting an estimated 1.3 billion people globally. The steepest increases showed up in countries at middle and high-middle levels of development, where diets and lifestyles are shifting rapidly.6PubMed Central. Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021
When researchers narrowed the lens to clinical and community studies, the pooled prevalence was even higher: roughly 39% across over three million individuals, likely reflecting that study participants are often drawn from groups with higher metabolic risk. Among lean individuals, the figure was around 5%, while nearly 30% of people classified as “nonobese” (a broader category that can include those who are mildly overweight) had MAFLD.7PubMed. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals Children are not spared either. In a global meta-analysis of overweight or obese children and adolescents, MAFLD prevalence reached about 34% in the general population and 45% in obesity clinic settings.8PubMed Central. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis
What Drives the Disease
At its core, MAFLD is about energy imbalance and insulin resistance. When the body takes in more fuel than it can burn or safely store in fat tissue, the surplus gets rerouted. Insulin resistance makes the problem worse: fat tissue becomes inflamed, releases more free fatty acids into the bloodstream, and the liver becomes the organ that absorbs the overflow.9PubMed Central. Role of Insulin Resistance in MAFLD Inflamed fat tissue also pumps out inflammatory signals that reach the liver and amplify the damage there.10Clinical Science. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
The liver has a large capacity to handle fat, but that capacity has limits. When the influx of fatty acids exceeds what the liver can safely burn or export, toxic fat-derived molecules accumulate. These trigger stress responses within liver cells, damaging their internal machinery and eventually killing them off. That ongoing injury is what separates simple fat accumulation from the more dangerous inflammatory stage.11PubMed. Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
The gut also plays a role. In people with advanced fatty liver disease, the intestinal barrier can become leaky, allowing bacterial toxins and inflammatory signals to travel from the gut to the liver through the portal vein. This so-called gut-liver axis adds another layer of inflammation and injury.12PubMed Central. Gut microbiota in MAFLD: therapeutic and diagnostic implications A disrupted gut microbiome, with fewer beneficial bacteria and more inflammatory byproducts, appears to worsen steatosis, inflammation, and fibrosis alike.13PubMed Central. From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease
How the Disease Progresses
MAFLD sits on a spectrum. The earliest stage is plain steatosis, where fat accumulates in liver cells but no significant inflammation or scarring is present. Many people stay at this stage for years or even decades. But in a subset of patients, the disease progresses to steatohepatitis, where active inflammation damages liver cells and the liver begins to scar. Fibrosis (scarring) is the factor that most determines a person’s long-term outlook. Severe fibrosis can advance to cirrhosis, which replaces healthy liver tissue with scar tissue and may eventually lead to liver failure or liver cancer.14PubMed Central. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review15PubMed. Natural history of metabolic dysfunction-associated steatotic liver disease
Progression is not inevitable. In a Danish tertiary liver center that re-biopsied patients over time, about 28% of those with simple steatosis progressed to steatohepatitis, but a third of those who already had steatohepatitis actually regressed back to simple steatosis. Similarly, roughly two-thirds of patients had stable fibrosis on follow-up, and about 13% saw their fibrosis improve.16PubMed Central. Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center The disease can go backward, which is one of the most hopeful things about it.
Liver Cancer Without Cirrhosis
A troubling feature of fatty liver disease is that liver cancer (hepatocellular carcinoma, or HCC) can develop even without cirrhosis. In most other liver diseases, cirrhosis is the main precursor, and surveillance programs are built around screening patients who have it. But a meaningful fraction of MAFLD-related liver cancers arise in people whose livers are not yet cirrhotic, which means these cancers can go undetected until they are advanced.17PubMed Central. Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease The per-year risk in any individual without cirrhosis is low, but because so many people worldwide have fatty liver disease, the absolute number of cancers adds up.
Type 2 diabetes appears to amplify cancer risk even in pre-cirrhotic stages. In a study comparing patients with and without cirrhosis who developed HCC from fatty liver disease, male sex and a higher fibrosis score were among the strongest risk factors for cancer in the non-cirrhotic group. People diagnosed without cirrhosis did, however, tend to have better survival outcomes, partly because they did not face the added burden of liver failure from end-stage scarring.18PubMed. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis
Heart Disease Is the Leading Killer
Here is something many people do not realize: the most common cause of death in people with MAFLD is not liver failure. It is cardiovascular disease. A meta-analysis found that the risk of developing or dying from cardiovascular disease was roughly double in people with MAFLD compared to those without it. The incidence of cardiovascular events was more than twice as high, and cardiovascular mortality was about 57% higher.19PubMed Central. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis MAFLD is also linked to hypertension, atherosclerosis, heart muscle disease, and chronic kidney disease, suggesting the metabolic dysfunction at its root affects the entire vascular system, not just the liver.20PubMed Central. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
The relationship between MAFLD and type 2 diabetes is especially tight and bidirectional: diabetes worsens liver fat and fibrosis, and fatty liver worsens insulin resistance and blood sugar control.21FOCUS. Endocrinology. Diabetes mellitus and liver: Non-obvious aspects This feedback loop is one reason doctors increasingly view MAFLD not as a standalone liver problem but as a signal of systemic metabolic risk that deserves attention across specialties.
Lean MAFLD
One of the more counterintuitive aspects of this condition is that you do not need to be overweight to have it. “Lean MAFLD” describes people with a normal body mass index who still develop metabolic fatty liver disease. These individuals tend to be older and more often female than their overweight counterparts. In one Taiwanese study, about a quarter of lean MAFLD patients also had diabetes. After adjusting for age and sex, lean patients had lower fibrosis scores on average but a higher rate of carotid plaques, a marker of atherosclerosis. Lean patients with concurrent diabetes actually had the highest risk of atherosclerosis among all MAFLD subtypes, while overweight patients with diabetes had the highest risk of advanced liver scarring.22PubMed Central. Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus
Lean MAFLD challenges the common assumption that fatty liver is purely a consequence of being heavy. Genetics, body fat distribution (especially visceral fat around internal organs), gut microbiome differences, and hormonal factors all contribute. If you are lean but have metabolic risk factors like high blood pressure, abnormal triglycerides, or insulin resistance, fatty liver is not off the table.
Sex Differences and the Role of Hormones
Men develop MAFLD at higher rates than premenopausal women, and when they do, their fibrosis tends to be more severe at the same level of inflammation. A large study found that men and postmenopausal women had roughly 60% to 70% higher odds of more advanced fibrosis compared to premenopausal women, even after accounting for inflammation severity. Before age 50, men had about 80% higher odds of more severe fibrosis than women of the same age.23PubMed Central. Gender and Menopause Impact Severity of Fibrosis Among Patients with Nonalcoholic Steatohepatitis After age 50, that protective effect in women disappeared, strongly suggesting that estrogen plays a role in shielding the liver from scarring.
This has real-world implications for women going through menopause, who should be aware that their liver risk profile shifts. Conditions like polycystic ovary syndrome, which involves hormonal imbalances and insulin resistance, are also associated with higher fatty liver risk. And in men, low testosterone (hypogonadism) has been linked to metabolic dysfunction and increased susceptibility to fatty liver.24PubMed Central. Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Screening and Non-Invasive Tests
Given how widespread MAFLD is and how silently it progresses, screening matters. Most people with fatty liver have no symptoms until the disease is advanced. Experts have called for universal non-invasive screening in people who already show metabolic dysfunction, using combinations of blood tests, imaging, and clinical risk scores that a primary care physician can apply.25PubMed Central. Screening for MAFLD: who, when and how?
For detecting fibrosis specifically, a technique called magnetic resonance elastography (MRE) has emerged as the most accurate non-invasive tool. It measures liver stiffness using an MRI-based method and consistently outperforms ultrasound-based elastography (known as VCTE or FibroScan) at every fibrosis stage. In one systematic review comparing the two head-to-head in patients with confirmed fatty liver disease, MRE had higher accuracy across all stages of scarring.26PubMed Central. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? The catch is that MRE is expensive and not available everywhere, so blood-based scores and ultrasound elastography remain the workhorses for initial screening.
These blood-based scores are not perfect across all groups, though. A large multinational study found that the accuracy of one widely used score (FIB-4) declined in people over 65 and in middle-aged patients with type 2 diabetes. Ultrasound-based stiffness measurements held up well regardless of diabetes status but lost some accuracy in people with severe obesity.27PubMed. Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study Knowing these blind spots is important: if you are over 65, have diabetes, or have severe obesity, a single normal screening result may deserve a second look.
Treatment Through Lifestyle Changes
No pill currently cures MAFLD, though that is changing. The cornerstone of treatment remains weight loss through dietary changes and exercise. Losing 7% to 10% of body weight has been shown to improve liver fat, inflammation, and even fibrosis.28PubMed Central. Mediterranean diet and nonalcoholic fatty liver disease The Mediterranean diet, which emphasizes vegetables, fruits, whole grains, fish, and olive oil while limiting processed foods and added sugars, has accumulated strong evidence. A meta-analysis of randomized controlled trials found that the Mediterranean diet and aerobic exercise, whether alone or in combination with resistance training, support weight loss and improve liver health in MAFLD patients.29PubMed Central. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
The practical challenge, of course, is sustaining those changes over years. That is why pharmacological and surgical options are increasingly part of the conversation.
Emerging Medications and Surgery
The drug landscape for fatty liver disease has shifted dramatically. Resmetirom, a thyroid hormone receptor agonist, became the first medication specifically approved for the inflammatory stage of the disease. A network meta-analysis comparing three drug classes found that resmetirom produced the largest reduction in liver fat on imaging and significantly lowered liver enzyme levels. GLP-1 receptor agonists (the same drug class behind semaglutide and liraglutide) and FGF21 analogs also reduced liver enzymes, with FGF21 analogs showing especially strong rates of steatohepatitis resolution. Resmetirom did carry a higher rate of adverse events than the other two classes.30PubMed Central. Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
For people with severe obesity who have not responded to lifestyle changes alone, bariatric surgery has shown striking results. A meta-analysis reported pooled remission rates of 70% for steatohepatitis, 57% for fibrosis, and 59% for type 2 diabetes after surgery. Both sleeve gastrectomy and Roux-en-Y gastric bypass achieved similar metabolic and liver benefits, suggesting that the improvements go beyond simple weight loss and involve changes in gut hormones and insulin sensitivity.31PubMed. Metabolic and bariatric surgery in MAFLD: a meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications
Fatigue, Depression, and Quality of Life
MAFLD is not just a silent lab abnormality for many people. Patients often report fatigue, low mood, and disrupted sleep that significantly affect daily life. In one study, nearly half of NAFLD patients had clinically significant fatigue compared to about 29% of matched controls, and their depression scores were meaningfully higher.32PubMed Central. Reduced Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease May Be Associated with Depression and Fatigue A separate study painted an even starker picture: fatigue was reported by about 68% of MAFLD patients, depression by 75%, and sleep disorders by 63%, all vastly higher than rates in a control group.33European Journal of Gastroenterology & Hepatology. Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases
These symptoms are easy to dismiss as unrelated to liver health, but they track with metabolic inflammation and likely share the same underlying drivers. If you have been diagnosed with fatty liver disease and are dealing with persistent tiredness or low mood, it is worth raising that with your doctor rather than assuming it is a separate issue.
The Growing Economic Burden
MAFLD’s financial footprint is enormous and growing. Projections for the inflammatory form of the disease (MASH) estimate that annual direct healthcare costs in the United States alone will more than double from roughly $35 billion to nearly $79 billion by 2040. Productivity losses in the U.S. are projected to reach about $247 billion by that same year. The pattern repeats across the globe: in the UK, direct costs are expected to climb from about $2.2 billion to $5.3 billion, and in Brazil from $3.4 billion to $9.8 billion.34Clinical Gastroenterology and Hepatology. Global Economic and Clinical Burden of Metabolic Dysfunction-Associated Steatohepatitis
At the individual patient level, costs are heavily driven by hospitalization and advanced fibrosis. Patients with severe scarring (stage 3 or 4 fibrosis) generate disproportionately high costs, which makes a strong case for catching and treating the disease before it reaches those stages.35PubMed Central. Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost analysis from a tertiary-care, multidisciplinary MAFLD clinic The economics reinforce what the clinical data already suggest: early identification and management of metabolic risk factors is not just medically smart, it is the most cost-effective strategy available.